Literature DB >> 14586741

Roles of connective tissue growth factor and prostanoids in early streptozotocin-induced diabetic rat kidney: the effect of aspirin treatment.

Hisashi Makino1, Masashi Mukoyama, Akira Sugawara, Kiyoshi Mori, Takayoshi Suganami, Kensei Yahata, Yuriko Fujinaga, Hideki Yokoi, Issei Tanaka, Kazuwa Nakao.   

Abstract

BACKGROUND: Connective tissue growth factor (CTGF) is a cysteine-rich growth factor induced by transforming growth factor-beta (TGF-beta) and is thought to play a critical role in TGF-beta-stimulated extracellular matrix accumulation. To explore its involvement in early diabetic nephropathy, we investigated the time course of CTGF gene expression and its regulation in streptozotocin (STZ)-induced diabetic rat kidney.
METHODS: Northern blot analysis for CTGF, TGF-beta, and fibronectin expression was performed in the glomeruli of STZ-induced diabetic rats from 3 days to 12 weeks after the induction of diabetes, together with histological examination. To investigate the role of prostanoids in this process, aspirin was administered in one group of diabetic rats. Furthermore, CTGF expression was analyzed in rat mesangial cells cultured under high-glucose conditions.
RESULTS: Glomerular expression of CTGF and TGF-beta1 mRNA was coordinately upregulated as early as day 3, followed by fibronectin induction and mesangial matrix accumulation. Chronic aspirin treatment in diabetic rats significantly attenuated mesangial expansion, and effectively suppressed CTGF induction, as well as inhibiting the upregulation of TGF-beta1 and fibronectin expression. In cultured mesangial cells, aspirin treatment abolished high glucose-stimulated CTGF upregulation.
CONCLUSIONS: These results indicate that CTGF expressed in the glomeruli is upregulated in the early stage of STZ-induced diabetic nephropathy in rats, and could be a critical mediator of the development of diabetic glomerulosclerosis. In addition, the modulatory effects of aspirin during this process suggest a role of the cyclooxygenase pathway in the progression of diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14586741     DOI: 10.1007/s101570300004

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  9 in total

1.  Mastering a mediator: blockade of CCN-2 shows early promise in human diabetic kidney disease.

Authors:  Stephen M Twigg
Journal:  J Cell Commun Signal       Date:  2010-10-19       Impact factor: 5.782

2.  MicroRNA-26a inhibits TGF-β-induced extracellular matrix protein expression in podocytes by targeting CTGF and is downregulated in diabetic nephropathy.

Authors:  Kenichi Koga; Hideki Yokoi; Kiyoshi Mori; Masato Kasahara; Takashige Kuwabara; Hirotaka Imamaki; Akira Ishii; Keita P Mori; Yukiko Kato; Shoko Ohno; Naohiro Toda; Moin A Saleem; Akira Sugawara; Kazuwa Nakao; Motoko Yanagita; Masashi Mukoyama
Journal:  Diabetologia       Date:  2015-06-11       Impact factor: 10.122

3.  Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway.

Authors:  Guihua Zhou; Cai Li; Lu Cai
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

4.  Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling.

Authors:  Arthur C K Chung; Haiyan Zhang; Yao-Zhong Kong; Jia-Ju Tan; Xiao R Huang; Jeffrey B Kopp; Hui Y Lan
Journal:  J Am Soc Nephrol       Date:  2009-12-03       Impact factor: 10.121

5.  CREB trans-activation of disruptor of telomeric silencing-1 mediates forskolin inhibition of CTGF transcription in mesangial cells.

Authors:  Zhiyuan Yu; Qun Kong; Bruce C Kone
Journal:  Am J Physiol Renal Physiol       Date:  2010-01-06

6.  Inhibitors of Advanced Glycation End Product (AGE) Formation and Accumulation.

Authors:  Karly C Sourris; Anna Watson; Karin Jandeleit-Dahm
Journal:  Handb Exp Pharmacol       Date:  2021

7.  Systematic profiling of mRNA and miRNA expression in the pancreatic islets of spontaneously diabetic Goto-Kakizaki rats.

Authors:  Ling-Qin Zeng; Su-Bi Wei; Yi-Min Sun; Wen-Yan Qin; Jing Cheng; Keith Mitchelson; Lan Xie
Journal:  Mol Med Rep       Date:  2014-10-21       Impact factor: 2.952

8.  Strategies for blocking the fibrogenic actions of connective tissue growth factor (CCN2): From pharmacological inhibition in vitro to targeted siRNA therapy in vivo.

Authors:  David R Brigstock
Journal:  J Cell Commun Signal       Date:  2009-03-18       Impact factor: 5.782

9.  The transforming growth factor-beta pathway is a common target of drugs that prevent experimental diabetic retinopathy.

Authors:  Chiara Gerhardinger; Zeina Dagher; Paola Sebastiani; Yong Seek Park; Mara Lorenzi
Journal:  Diabetes       Date:  2009-04-28       Impact factor: 9.461

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.